The 5 most recent market catalysts affecting $MXCT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 3, 2026
Corporate Catalyst
Neutral
Impact 55
Liontrust Investment Partners Discloses 4.9% Stake in MaxCyte, Inc.
Liontrust Investment Partners has filed a Schedule 13D, revealing a 4.9% ownership stake in MaxCyte, Inc. This disclosure is significant as it indicates a substantial institutional…
Oct 14, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Wednesday's Intraday Session
This filing is not an 8-K in the traditional sense, but rather a news report from Benzinga's automated content engine summarizing intraday stock performance for a selection of heal…
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 75
MaxCyte Reports Preliminary Q3 Core Revenue Of ~$8.1M, Up 26% YoY; Raises FY26 Revenue Guidance To ~$34M, Core Business Revenue Outlook To ~$28M
MaxCyte announced preliminary Q3 2026 core business revenue of $8.1 million, representing a robust 26% year-over-year growth. This strong performance has led the company to raise i…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 75
MaxCyte Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $7.271M Beat $6.475M Estimate
MaxCyte's Q2 earnings report showed a smaller loss per share than anticipated and sales that exceeded analyst consensus. This indicates better-than-expected operational performance…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 65
MaxCyte Enters Into Technology License Partnership With Genentech To Support Development Of Cell Therapy Programs
MaxCyte announced a technology license partnership with Genentech, a subsidiary of Roche, granting Genentech access to MaxCyte's ExPERT GTx platform for cell therapy development. T…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.